Cellyan Biotechnology Co., Ltd
Cellyan Biotechnology Co., Ltd (HKPD) Stock Competitors & Peer Comparison
See (HKPD) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HKPD | $0.70 | +0.00% | 7.5M | 4.00 | $0.17 | N/A |
| ONC | $354.48 | +0.00% | 38.7B | 724.28 | $0.50 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | N/A |
| DFTX | $17.27 | +0.00% | 1.7B | N/A | N/A | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LFMDP | $22.70 | +0.00% | 998.4M | -10.06 | -$2.26 | N/A |
| CGEM | $13.88 | +0.00% | 806.4M | -4.11 | -$3.32 | N/A |
| ATAI | $3.82 | +0.00% | 731.9M | -4.67 | -$0.83 | N/A |
| HITI | $2.40 | +0.00% | 218.7M | -5.41 | -$0.46 | N/A |
Stock Comparison
HKPD vs ONC Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, ONC has a market cap of 38.7B. Regarding current trading prices, HKPD is priced at $0.70, while ONC trades at $354.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas ONC's P/E ratio is 724.28. In terms of profitability, HKPD's ROE is -0.01%, compared to ONC's ROE of +0.02%. Regarding short-term risk, HKPD is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check ONC's competition here
HKPD vs WBA Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, HKPD is priced at $0.70, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas WBA's P/E ratio is -1.64. In terms of profitability, HKPD's ROE is -0.01%, compared to WBA's ROE of -0.70%. Regarding short-term risk, HKPD is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check WBA's competition here
HKPD vs DFTX Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, DFTX has a market cap of 1.7B. Regarding current trading prices, HKPD is priced at $0.70, while DFTX trades at $17.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas DFTX's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.01%, compared to DFTX's ROE of -0.86%. Regarding short-term risk, HKPD is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check DFTX's competition here
HKPD vs HROWL Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, HKPD is priced at $0.70, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas HROWL's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.01%, compared to HROWL's ROE of -0.09%. Regarding short-term risk, HKPD is more volatile compared to HROWL. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check HROWL's competition here
HKPD vs HROWM Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, HKPD is priced at $0.70, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas HROWM's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.01%, compared to HROWM's ROE of -0.09%. Regarding short-term risk, HKPD is more volatile compared to HROWM. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check HROWM's competition here
HKPD vs LFMDP Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, LFMDP has a market cap of 998.4M. Regarding current trading prices, HKPD is priced at $0.70, while LFMDP trades at $22.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas LFMDP's P/E ratio is -10.06. In terms of profitability, HKPD's ROE is -0.01%, compared to LFMDP's ROE of +2.22%. Regarding short-term risk, HKPD is more volatile compared to LFMDP. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check LFMDP's competition here
HKPD vs CGEM Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, CGEM has a market cap of 806.4M. Regarding current trading prices, HKPD is priced at $0.70, while CGEM trades at $13.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas CGEM's P/E ratio is -4.11. In terms of profitability, HKPD's ROE is -0.01%, compared to CGEM's ROE of -0.42%. Regarding short-term risk, HKPD is less volatile compared to CGEM. This indicates potentially lower risk in terms of short-term price fluctuations for HKPD.Check CGEM's competition here
HKPD vs ATAI Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, ATAI has a market cap of 731.9M. Regarding current trading prices, HKPD is priced at $0.70, while ATAI trades at $3.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas ATAI's P/E ratio is -4.67. In terms of profitability, HKPD's ROE is -0.01%, compared to ATAI's ROE of -1.08%. Regarding short-term risk, HKPD is more volatile compared to ATAI. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check ATAI's competition here
HKPD vs HITI Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, HITI has a market cap of 218.7M. Regarding current trading prices, HKPD is priced at $0.70, while HITI trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas HITI's P/E ratio is -5.41. In terms of profitability, HKPD's ROE is -0.01%, compared to HITI's ROE of -0.40%. Regarding short-term risk, HKPD is more volatile compared to HITI. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check HITI's competition here
HKPD vs LFMD Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, LFMD has a market cap of 135.7M. Regarding current trading prices, HKPD is priced at $0.70, while LFMD trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas LFMD's P/E ratio is -11.28. In terms of profitability, HKPD's ROE is -0.01%, compared to LFMD's ROE of +2.22%. Regarding short-term risk, HKPD is more volatile compared to LFMD. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check LFMD's competition here
HKPD vs LFLY Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, LFLY has a market cap of 114.9M. Regarding current trading prices, HKPD is priced at $0.70, while LFLY trades at $37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas LFLY's P/E ratio is -0.04. In terms of profitability, HKPD's ROE is -0.01%, compared to LFLY's ROE of +0.25%. Regarding short-term risk, HKPD is less volatile compared to LFLY. This indicates potentially lower risk in terms of short-term price fluctuations for HKPD.Check LFLY's competition here
HKPD vs YI Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, YI has a market cap of 70.9M. Regarding current trading prices, HKPD is priced at $0.70, while YI trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas YI's P/E ratio is -2.82. In terms of profitability, HKPD's ROE is -0.01%, compared to YI's ROE of +0.11%. Regarding short-term risk, HKPD is more volatile compared to YI. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check YI's competition here
HKPD vs PETS Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, PETS has a market cap of 63.1M. Regarding current trading prices, HKPD is priced at $0.70, while PETS trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas PETS's P/E ratio is -0.95. In terms of profitability, HKPD's ROE is -0.01%, compared to PETS's ROE of -1.22%. Regarding short-term risk, HKPD is more volatile compared to PETS. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check PETS's competition here
HKPD vs RAD Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, HKPD is priced at $0.70, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas RAD's P/E ratio is -0.05. In terms of profitability, HKPD's ROE is -0.01%, compared to RAD's ROE of +2.76%. Regarding short-term risk, HKPD is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for HKPD.Check RAD's competition here
HKPD vs KYNB Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, KYNB has a market cap of 33.7M. Regarding current trading prices, HKPD is priced at $0.70, while KYNB trades at $7.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas KYNB's P/E ratio is -0.65. In terms of profitability, HKPD's ROE is -0.01%, compared to KYNB's ROE of -1.26%. Regarding short-term risk, HKPD is more volatile compared to KYNB. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check KYNB's competition here
HKPD vs RNTX Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, RNTX has a market cap of 31.8M. Regarding current trading prices, HKPD is priced at $0.70, while RNTX trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas RNTX's P/E ratio is -0.41. In terms of profitability, HKPD's ROE is -0.01%, compared to RNTX's ROE of -2.17%. Regarding short-term risk, HKPD is more volatile compared to RNTX. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check RNTX's competition here
HKPD vs POM Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, POM has a market cap of 23.7M. Regarding current trading prices, HKPD is priced at $0.70, while POM trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas POM's P/E ratio is -4.43. In terms of profitability, HKPD's ROE is -0.01%, compared to POM's ROE of +0.07%. Regarding short-term risk, HKPD is more volatile compared to POM. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check POM's competition here
HKPD vs MSLE Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, MSLE has a market cap of 14.5M. Regarding current trading prices, HKPD is priced at $0.70, while MSLE trades at $11.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas MSLE's P/E ratio is 4.37. In terms of profitability, HKPD's ROE is -0.01%, compared to MSLE's ROE of N/A. Regarding short-term risk, HKPD is more volatile compared to MSLE. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check MSLE's competition here
HKPD vs MEDS Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, HKPD is priced at $0.70, while MEDS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas MEDS's P/E ratio is -0.31. In terms of profitability, HKPD's ROE is -0.01%, compared to MEDS's ROE of -0.26%. Regarding short-term risk, HKPD is more volatile compared to MEDS. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check MEDS's competition here
HKPD vs CJJD Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, HKPD is priced at $0.70, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas CJJD's P/E ratio is -0.46. In terms of profitability, HKPD's ROE is -0.01%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, HKPD is more volatile compared to CJJD. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check CJJD's competition here
HKPD vs NEUP Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, NEUP has a market cap of 8.2M. Regarding current trading prices, HKPD is priced at $0.70, while NEUP trades at $4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas NEUP's P/E ratio is -1.08. In terms of profitability, HKPD's ROE is -0.01%, compared to NEUP's ROE of -0.08%. Regarding short-term risk, HKPD is more volatile compared to NEUP. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check NEUP's competition here
HKPD vs SSY Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, HKPD is priced at $0.70, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas SSY's P/E ratio is -2.86. In terms of profitability, HKPD's ROE is -0.01%, compared to SSY's ROE of -0.18%. Regarding short-term risk, HKPD is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for HKPD.Check SSY's competition here
HKPD vs AIXC Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, AIXC has a market cap of 6.4M. Regarding current trading prices, HKPD is priced at $0.70, while AIXC trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas AIXC's P/E ratio is 0.44. In terms of profitability, HKPD's ROE is -0.01%, compared to AIXC's ROE of -0.73%. Regarding short-term risk, HKPD is more volatile compared to AIXC. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check AIXC's competition here
HKPD vs BGMSP Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, BGMSP has a market cap of 6M. Regarding current trading prices, HKPD is priced at $0.70, while BGMSP trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas BGMSP's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.01%, compared to BGMSP's ROE of -7.22%. Regarding short-term risk, HKPD is more volatile compared to BGMSP. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check BGMSP's competition here
HKPD vs MDVL Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, HKPD is priced at $0.70, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas MDVL's P/E ratio is -0.05. In terms of profitability, HKPD's ROE is -0.01%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, HKPD is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for HKPD.Check MDVL's competition here
HKPD vs ATNFW Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, HKPD is priced at $0.70, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas ATNFW's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.01%, compared to ATNFW's ROE of -1.93%. Regarding short-term risk, HKPD is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for HKPD.Check ATNFW's competition here
HKPD vs NVOH Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, NVOH has a market cap of 2.3M. Regarding current trading prices, HKPD is priced at $0.70, while NVOH trades at $26.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas NVOH's P/E ratio is 13.37. In terms of profitability, HKPD's ROE is -0.01%, compared to NVOH's ROE of +0.00%. Regarding short-term risk, HKPD is more volatile compared to NVOH. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check NVOH's competition here
HKPD vs BGMS Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, HKPD is priced at $0.70, while BGMS trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas BGMS's P/E ratio is -0.07. In terms of profitability, HKPD's ROE is -0.01%, compared to BGMS's ROE of -1.87%. Regarding short-term risk, HKPD is more volatile compared to BGMS. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check BGMS's competition here
HKPD vs AZNH Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, HKPD is priced at $0.70, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas AZNH's P/E ratio is 38.35. In terms of profitability, HKPD's ROE is -0.01%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, HKPD is more volatile compared to AZNH. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check AZNH's competition here
HKPD vs LFLYW Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, HKPD is priced at $0.70, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, HKPD's ROE is -0.01%, compared to LFLYW's ROE of +0.25%. Regarding short-term risk, HKPD is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check LFLYW's competition here
HKPD vs BIMI Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, BIMI has a market cap of 1.2K. Regarding current trading prices, HKPD is priced at $0.70, while BIMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas BIMI's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.01%, compared to BIMI's ROE of -2.94%. Regarding short-term risk, HKPD is more volatile compared to BIMI. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check BIMI's competition here
HKPD vs POZN Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, POZN has a market cap of 0. Regarding current trading prices, HKPD is priced at $0.70, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas POZN's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.01%, compared to POZN's ROE of +0.61%. Regarding short-term risk, HKPD is less volatile compared to POZN. This indicates potentially lower risk in terms of short-term price fluctuations for HKPD.Check POZN's competition here
HKPD vs IPXL Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, HKPD is priced at $0.70, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas IPXL's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.01%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, HKPD is more volatile compared to IPXL. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check IPXL's competition here
HKPD vs ESRX Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, HKPD is priced at $0.70, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas ESRX's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.01%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, HKPD is more volatile compared to ESRX. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check ESRX's competition here
HKPD vs CPD Comparison February 2026
HKPD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HKPD stands at 7.5M. In comparison, CPD has a market cap of 0. Regarding current trading prices, HKPD is priced at $0.70, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HKPD currently has a P/E ratio of 4.00, whereas CPD's P/E ratio is N/A. In terms of profitability, HKPD's ROE is -0.01%, compared to CPD's ROE of N/A. Regarding short-term risk, HKPD is more volatile compared to CPD. This indicates potentially higher risk in terms of short-term price fluctuations for HKPD.Check CPD's competition here